Search - tctmd.com

Displaying 61 - 80 of 204

Sort: Relevancy | Date

Presentation TCT 2020

Where Are We With the Data on Paclitaxel?

Presenter: Eric Secemsky

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

Presentation TCT 2020

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

Presenter: Andrew Holden

October 18, 2020

Presentation TCT 2020

TCT 370: A Patient-Level, Pooled Analysis of Mortality Rates With the Passeo-18 Lux Paclitaxel Drug-Coated Balloon in Peripheral Arterial Disease

Presenter: Brian Forrestal

October 14, 2020

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

Presentation TCT 2019

Paclitaxel-Coated Balloons for Coronary Intervention: Critical Review of Long-Term Trial Data in Light of the PAD Controversy — The DAEDALUS Collaboration

Presenter: Robert Byrne

September 28, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

Presentation TCT 2019

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Presenter: Thomas Zeller

September 27, 2019

Presentation TCT 2019

Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoro-Popliteal Occlusive Disease: 3-Year Clinical and Ambulatory Outcome

Presenter: Piotr Buszman

September 27, 2019

Presentation TCT 2019

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Presenter: Sandeep Basavarajaiah

September 27, 2019

Presentation TCT 2019

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Presenter: Bruno Scheller

September 27, 2019

Presentation TCT 2019

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Presenter: Aravinda Nanjundappa

September 27, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Advertisement

Where Are We With the Data on Paclitaxel?

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

TCT 370: A Patient-Level, Pooled Analysis of Mortality Rates With the Passeo-18 Lux Paclitaxel Drug-Coated Balloon in Peripheral Arterial Disease

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

Paclitaxel-Coated Balloons for Coronary Intervention: Critical Review of Long-Term Trial Data in Light of the PAD Controversy — The DAEDALUS Collaboration

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoro-Popliteal Occlusive Disease: 3-Year Clinical and Ambulatory Outcome

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content